Detection of Circulating Endothelial Progenitor Cells (EPCs) in Peripheral Blood From Non-small Cell Lung Cancer Patients
The aim of this study is to study blood circulating levels bone-marrow-derived progenitor
In a first phase, EPCs will be detected in healthy non-smokers volunteers to validate flow
cytometry method (n=25). In addition, EPC will e characterized by primary cultures to
analyze EPC-specific markers.
In a second phase, EPCs will detect in peripheral blood from 50 patients with Chronic
Obstructive Pulmonary Disease (COPD) and 50 patients with non-small cell lung cancers
(NSCLC). Primary cultures will be made to confirm EPCS isolation.
Methods: EPCs will be numerated by flow cytometry using CD133, CD146, CD34, CD45 and VEGFR2
antibodies. Primary cultures will be used to identify EPCs at 5-days culture by the same
markers. In addition, for BPCO et NSCLC patients, Vascular endothelial cell growth factor
(VEGF) concentration will be measured in peripheral sera by ELISA commercial test.
Overall survival will be analyzed for NSCLC in function of initial EPCs concentration.
Correlation will be studied between initial VEGF serum concentration and EPCs level.
This study focus on the possibility that EPC determination in peripheral blood could be used
as a surrogate marker of standard or antiangiogenic treatment in NSCLC.
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Number of EPCs in peripheral blood from NSCLC patients. Comparison with healthy non-smokers patients and smokers with COPD.
at the end of the first step of the study (2 months after the beguening of the study)
Boris MELLONI, Professor
Service de pneumologie,chu Limoges
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)